Vedolizumab for Inflammatory Bowel Disease: Changing the Game, or More of the Same?

United European Gastroenterology Journal- United States

doi 10.1177/2050640614550672

Full Text

Abstract

Available in

Categories

Gastroenterology

Date

September 22, 2014

Authors

Publisher

SAGE Publications

Related search

Letter: Vedolizumab for Autoimmune Liver Disease Associated Inflammatory Bowel Disease-Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

Digestive Diseases and Sciences

Gastroenterology

English

Letter: Vedolizumab for the Management of Inflammatory Bowel Disease in Patients After Liver Transplantation for Primary Sclerosing Cholangitis

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Vedolizumab Exposure in Pregnancy: Outcomes From Clinical Studies in Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Review Article: Predictors of Response to Vedolizumab and Ustekinumab in Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

One-Year Effectiveness and Safety of Vedolizumab Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Cohort Study

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

The Treatment of Inflammatory Bowel Disease With 6-Mercaptopurine or Azathioprine

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN

Journal of Crohn's and Colitis

Gastroenterology

English

Rifaximin for Inflammatory Bowel Disease

Digestive Diseases and Sciences

Gastroenterology

English